Targets › GR
1 program from 1 company in 1 trial: 1 Phase 4; Respiratory; next expected readout Apr 2028.
Open in Phaseline: the race on GR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Miami | Albuterol-Budesonide (AIRSUPRA) Fast-acting beta-2 agonist and inhaled corticosteroid combination | ADRB2, GR | Phase 4 | Asthma | Apr 2028 |
Asthma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.